Inve India ▾

Marksans Pharma share price & results

Marksans Pharma Limited· Healthcare

Results to
Jun 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

Mumbai pharma maker of OTC/Rx generics sold as store-brand & own-label products in US, UK, Australia/NZ, RoW.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue321 ₹ crore+0.3% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin26.0 %+4.0 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit69.0 ₹ crore+43.8% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equity18.83 %−1.6 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin11.11 %+9.8 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)19.57 %−8.0 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

4 of 5 judged targets kept · 13 open · verdicts reflect calls analysed to Q1 FY27.

Marksans Pharma Limited management guidance track record on Inve: 18 targets tracked across analysed earnings calls (4 achieved, 1 missed, 13 open).

TargetOriginal wordingSaidLatest callVerdict
Operating RevenueRs. 3,000 crores for FY26
Call transcript, Q4 FY25 · 20 May 2025		Q4 FY25Q1 FY27:Target period (FY26) has passed. Final verdict stands.
Call transcript, Q1 FY27 · 13 Aug 2026		Achieved*
Teva Facility RevenueHit Rs. 1,000 crores eventually
Call transcript, Q4 FY25 · 20 May 2025		Q4 FY25Q1 FY27:No specific update on the Teva facility revenue. A separate target for 'Goa Unit 2' was mentioned, but its relation to the larger Teva facility is unclear.
Call transcript, Q1 FY27 · 13 Aug 2026		Ghosted
Operating RevenueDouble revenue in the next 3 to 5 years (from ~INR 3,000 cr base).
Call transcript, Q4 FY26 · 27 May 2026		Q4 FY26Q1 FY27:Management reiterated the goal but softened the timeline from '3 to 5 years' to 'within the next five years'.
Call transcript, Q1 FY27 · 13 Aug 2026		Diluted

Source: Inve Guidance Tracker for Marksans Pharma Limited · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

1 of Marksans Pharma Limited's 18 targets was missed. See which ones, and which are quietly gone. The 3 above are the free sample; 15 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹296.65 +3.40% · +₹9.75

Last close 26 Oct 2026 · NSE · INR · Source: Inve

Performance +67.9% 1Y

₹150₹200₹250₹300₹350Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q2 FY26 — 14 Nov 2025Q3 FY26 — 6 Feb 2026Q4 FY26 — 27 May 2026Q1 FY27 — 13 Aug 2026

1Y: ₹176.7 on 24 Oct 2025 → ₹296.65. High ₹347.6 (23 Sept 2026), low ₹156.89 (30 Mar 2026).

Previous close
₹286.9
Market cap
₹13.4k Cr
52-week range
₹156.89 – ₹347.6
One year
+66.54%
Price to earnings (TTM to Jun 2026)
26.00×
Return on equity (TTM to Jun 2026)
18.83%

Overview

Symbol
NSE:MARKSANS
Exchange
NSE
Currency
INR

What Marksans Pharma Limited does

Based on the company's own presentations, annual report and earnings calls.

Marksans Pharma manufactures and sells over-the-counter (OTC) and prescription (Rx) generic pharmaceutical products, largely as private-label/store-brand manufacturing for retailers as well as its own-label products, across categories such as pain management, cough & cold, gastrointestinal, cardiovascular, CNS and vitamins/minerals & supplements. It operates four manufacturing units — Farmingdale (USA), Southport (UK) and two units in Goa (India) — backed by four R&D centres, supporting a portfolio of 350+ approved products and 2,000+ SKUs. Its largest market is the US & North America (via subsidiary Time Cap Laboratories), followed by UK & Europe (via Bell, Sons & Co. and Relonchem) and Australia & New Zealand (via Nova Pharmaceuticals, including its newly launched Rx brand division Nova Pharma), with a smaller Rest-of-World business across the CIS and MENA regions including the UAE (via Access Healthcare, Dubai).

Segments

  • OTC (Over-the-counter)
  • Rx (Prescription / branded generics)
Manufacturing facilities
4 units — Farmingdale (USA), Southport (UK), and 2 units in Goa (India) — plus 4 R&D centres
Installed manufacturing capacity
~26 billion units per annum across all facilities combined
Products and SKUs
350+ products and 2,000+ SKUs
ANDAs / Marketing Authorizations
350+ approved, 30+ filed and awaiting approval, 200+ additional products in pipeline
R&D scientists
50+ scientists across 4 R&D centres (Farmingdale US, Southport UK, Goa and Navi Mumbai, India)
Geographic footprint
Direct presence in the US, UK, Australia & New Zealand, Germany, Ireland, Canada and the UAE; RoW business spans 13 countries across CIS and MENA
Founded 2001Headquarters Mumbai, India Company website

How the price took the results

close before → close after

Q1 FY27
−2.9%
13 Aug
Q4 FY26
−2.2%
27 May
Q3 FY26
−1.2%
6 Feb
Q2 FY26
+2.2%
14 Nov

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Marksans Pharma Limited

Free account: one company. Everything above stays public.

Write why you follow Marksans Pharma Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Marksans Pharma Limited

Guides on how to read this kind of business and the numbers that matter.